You have no items in your shopping cart.
ABSTRACT
Asthma, a chronic inflammatory respiratory condition, has been increasingly associated with systemic effects, including potential impacts on liver function. This study aimed to investigate the effects of ovalbumin (OVA)-induced asthma on liver function in female Sprague-Dawley rats treated with salbutamol, hydrocortisone, montelukast, and prednisolone. Forty-two female Sprague-Dawley rats were randomly assigned to seven groups, including control, asthma-induced, and treatment groups receiving Salbutamol, Prednisolone, Hydrocortisone and Montelukast. Asthma was induced using 1 mg ovalbumin and 20 mg aluminium hydroxide (I.p.) for sensitization and 1 mg w/v aerosolised ovalbumin biweekly for 28 days, and treatment with salbutamol, hydrocortisone, montelukast and prednisolone administered for four weeks. Statistical analysis was performed by one-way analysis of variance (One-way Anova). Results indicated that montelukast significantly reduced ALT and AST, and total protein levels compared to negative and positive control groups (p<0.05, respectively). Corticosteroids (prednisolone and hydrocortisone) and salbutamol have no effects on liver function parameters compared to control (>0.05). In conclusion, this study highlights the hepatoprotective potential of montelukast in mitigating liver damage associated with OVA-induced asthma.
